Aryl ether-substituted heterocyclic compounds as GLP1R agonists
A novel aryl ether substituted heterocyclic compound has GLP1R agonist activity. A GLP1R agonist is represented by formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, isotope substituent or isomer thereof.
1 . A compound, which is:
or a pharmaceutically acceptable salt, solvate, enantiomer, or isotopic variation thereof.
2 . The compound of claim 1 , which is:
or a pharmaceutically acceptable salt thereof.
3 . The compound of claim 1 , which is:
or a pharmaceutically acceptable salt.
4 . The compound of claim 1 , which is:
or a pharmaceutically acceptable salt.
5 . A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 .
6 . A method of treating obesity or diabetes in a subject in need thereof, comprising administering a therapeutically effective amount of the compound of claim 1 to the subject.